NCT06893887 2025-07-02
ICT-HCC
Nanjing Tianyinshan Hospital
Phase NA Recruiting
Clinical Trials
13 trialsNCT03228043 2024-11-14
Apatinib for Resectable Colorectal Cancer
Nanchong Central Hospital
Phase NA Withdrawn
NCT04559607 2023-12-18
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
Phase NA Unknown
NCT03743428 2023-06-29
BABST-C
Shenzhen People's Hospital
Phase NA Suspended
NCT05653817 2022-12-16
Advanced or Metastatic Cholangiocarcinoma
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT02764268 2022-03-11
Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase NA Completed
NCT03349827 2020-03-24
HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer
Wuhan University
Phase NA Terminated
NCT04174339 2019-11-22
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase NA Unknown
NCT03671265 2019-01-09
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT03722875 2018-12-19
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT03398122 2018-01-12
HCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT03255811 2017-08-21
Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer
Guangdong Provincial People's Hospital
Phase NA Unknown
NCT03066557 2017-02-28
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Jiangsu Cancer Institute & Hospital
Phase NA Unknown